EDGAR·FLOW

Amylyx Pharmaceuticals, Inc. — Form 8-K

Filed November 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Amylyx announced positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, showing 55% reduction in hypoglycemic events vs. placebo (p=0.000003) with all secondary endpoints met. The company completed an upsized public offering generating net proceeds of $544.6 million, increasing cash position from $250.8M (June 30, 2026) to $768.1M (September 30, 2026). NDA submission remains on track for end of 2026; commercial team buildout underway for potential 2027 launch. Q3 2026 net loss was $45.5M ($0.38/share) on R&D expenses of $28.4M and SG&A of $21.3M.
Why this rating

Transformational clinical validation ($545M capital raise = 105% of market cap) de-risks regulatory path, but company remains pre-revenue and loss-making with significant execution risk ahead.

Tradability signal
NO TRADE

No trade: the filing reads positive but the market is selling it (-4.4% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$29.85
+10 min · unknown
$29.70 ▼ 0.50%
+30 min · unknown
$29.34 ▼ 1.69%
+1 hr · unknown
$29.45 ▼ 1.34%
+4 hrs · unknown
$28.40 ▼ 4.86%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ AMLX · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.